DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Comparing the Effect of Vaginal Misoprostol With Dinoprostone in Term Pregnancies

Information source: Hormozgan University of Medical Sciences
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Preeclampsia; Fetal Death; Fetal Membranes, Premature Rupture

Intervention: misoprostol (Drug); dinoprostone (Drug)

Phase: Phase 1/Phase 2

Status: Not yet recruiting

Sponsored by: Hormozgan University of Medical Sciences

Official(s) and/or principal investigator(s):
Mitra Ahmad Soltani, Principal Investigator, Affiliation: Hormozgan University of Medical Sciences
Minoo Rajaee Lari, Perinatologist - Obs and Gyn, Study Chair, Affiliation: Department of Obs and Gyn - HUMS


Hypothesis (H0): Labor duration and obstetric complications are not significantly different in the three groups (misoprostol-dinoprostone-oxytocin).

Clinical Details

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Minimum age: N/A. Maximum age: N/A. Gender(s): Female.


Inclusion Criteria:

- Term pregnancy

- Singleton

- Vertex

- Bishop score below 6

Exclusion Criteria:

- History of drug reaction

- Medical disease


- Oligohydramnios

- Vaginal bleeding

- Fetal anomaly

- Uterine scar

Locations and Contacts

Shariaty Maternity Hospital, Tehran, Iran, Islamic Republic of; Not yet recruiting
Mitra Ahmad Soltani, MD, Phone: 0098 021 22301004, Email: m_a_sol@yahoo.com
Additional Information

Last updated: May 31, 2007

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017